Biopharma Roivant's Q2 income from operations misses

Reuters11-10

Biopharma Roivant's <a href="https://laohu8.com/S/QTWO">Q2</a> income from operations misses

Overview

Roivant Q2 revenue declines, missing analyst expectations for income from operations
Company maintains strong cash position of $4.4 bln, supporting cash runway into profitability
Brepocitinib Phase 3 study in dermatomyositis shows significant improvement over placebo

Outlook

Roivant plans NDA filing for brepocitinib in DM in H1 2026
Immunovant expects TED study results in H1 2026

Result Drivers

Research and development (R&D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue		$1.57 mln
Q2 EPS		-$0.17
Q2 Net Income		-$166.04 mln
Q2 Income From Operations	Miss	-$306.23 mln	-$278.40 mln (7 Analysts)
Q2 Operating Expenses		$307.80 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62

Press Release: ID:nGNX9SlRMC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582875586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582875586","market":"fut","top_or_hot":-1,"title":"Biopharma Roivant's Q2 income from operations misses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma Roivant's <a href=\"https://laohu8.com/S/QTWO\">Q2</a> income from operations misses</title></head><body><p><span>Overview</span></p><ul><li><p>Roivant Q2 revenue declines, missing analyst expectations for income from operations</p></li><li><p>Company maintains strong cash position of $4.4 bln, supporting cash runway into profitability</p></li><li><p>Brepocitinib Phase 3 study in dermatomyositis shows significant improvement over placebo</p></li></ul><p><span>Outlook</span></p><ul><li><p>Roivant plans NDA filing for brepocitinib in DM in H1 2026</p></li><li><p>Immunovant expects TED study results in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td></td><td><p>$1.57 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.17</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$166.04 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td><p>Miss</p></td><td><p>-$306.23 mln</p></td><td><p>-$278.40 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$307.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62</p></li></ul><p>Press Release: <span>ID:nGNX9SlRMC</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharma Roivant's Q2 income from operations misses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharma Roivant's Q2 income from operations misses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma Roivant's <a href=\"https://laohu8.com/S/QTWO\">Q2</a> income from operations misses</title></head><body><p><span>Overview</span></p><ul><li><p>Roivant Q2 revenue declines, missing analyst expectations for income from operations</p></li><li><p>Company maintains strong cash position of $4.4 bln, supporting cash runway into profitability</p></li><li><p>Brepocitinib Phase 3 study in dermatomyositis shows significant improvement over placebo</p></li></ul><p><span>Outlook</span></p><ul><li><p>Roivant plans NDA filing for brepocitinib in DM in H1 2026</p></li><li><p>Immunovant expects TED study results in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td></td><td><p>$1.57 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.17</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$166.04 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td><p>Miss</p></td><td><p>-$306.23 mln</p></td><td><p>-$278.40 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$307.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62</p></li></ul><p>Press Release: <span>ID:nGNX9SlRMC</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0D9:1","article_id":"2582875586","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582875586","pubTimestamp":1762776864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biopharma Roivant's Q2 income from operations missesOverviewRoivant Q2 revenue declines, missing analyst expectations for income from operationsCompany maintains strong cash position of $4.4 bln, supp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","ROIV":"Roivant Sciences Ltd.","BK4007":"制药","BK4588":"碎股","IMVT":"Immunovant, Inc."},"translate_title":"生物制药Roivant第二季度运营收入未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":0.9,"ROIV":0.9},"content_text":"Biopharma Roivant's Q2 income from operations missesOverviewRoivant Q2 revenue declines, missing analyst expectations for income from operationsCompany maintains strong cash position of $4.4 bln, supporting cash runway into profitabilityBrepocitinib Phase 3 study in dermatomyositis shows significant improvement over placeboOutlookRoivant plans NDA filing for brepocitinib in DM in H1 2026Immunovant expects TED study results in H1 2026Result DriversResearch and development (R&D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ2 Revenue$1.57 mlnQ2 EPS-$0.17Q2 Net Income-$166.04 mlnQ2 Income From OperationsMiss-$306.23 mln-$278.40 mln (7 Analysts)Q2 Operating Expenses$307.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62Press Release: ID:nGNX9SlRMCFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582875586","isCrawlerRequest":true}